American Journal of Hematology

Article	Citations
	538
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	294
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	293
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	170
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	166
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	151
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	141
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	127
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	114
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	109
Are veterans at increased risk of myeloproliferative neoplasms?	107
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	97
Acute thrombocytopenia suggesting thrombotic microangiopathy	77
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	77
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	75
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	73
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	71
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	71
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	70
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	68
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	68
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	67
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	67
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	65
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	62

History of Thrombosis at High Altitude Associates With Increased Erythropoietin	61
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	60
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	59
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	58
Clonal Hematopoiesis and Thrombosis	57
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	55
Teclistamab in patients with multiple myeloma and impaired renal function	55
The latest insights into rare blood disorders: Diagnosis and treatment strategies	55
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	54
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	53
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	52
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	50
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	49
Molecular and clinicopathologic characterization of pediatric histiocytoses	48
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	48
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	47
Table of Contents	46
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis	44
	44
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	42
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease‐positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial	42
Rare circulating lymphoblasts with striking eosinophilia: A rare case of B‐lymphoblastic leukemia with PAX5::ZCCHC7	41
International Consensus Classification for myeloid neoplasms at‐a‐glance	40
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)	40
Toward an improved understanding of hypomethylating agent and venetoclax therapies	40
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort	40
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (	40
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	39
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring	38
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients	38
Novel, de novo, beta‐globin variant with decreased oxygen affinity (HBB:c.317T>A, “Hemoglobin St. George”) in a healthy child with low oxygen saturations and ane	38
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study	37
Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors: A Machine Learning Approach	37
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	37
A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort	37
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource	36
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β0 Thalassemia Major Patient	36
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)	36
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficien	36
Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products	35
Impact of Switching From Race‐Based to Race‐Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia	35
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	33
Hydroxyurea in pregnancy: Reframing the conversation	33
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	33
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	33
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants	32
Peak absolute lymphocyte count after CAR‐T infusion predicts clinical response in aggressive lymphoma	32
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases	32
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurre	32
Impaired pro‐resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease	32

POEMS syndrome: Update on diagnosis, risk‐stratification, and management	32
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	32
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	32
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	31
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors	30
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy	30
Myelokathexis in an 18‐year‐old male patient with severe neutropenia and lymphopenia	30
Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study	30
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies	30
Issue Information	30
A case of peripheral T‐cell lymphoma, NOS, mimicking acute monocytic leukemia	29
A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia	29
Transient receptor potential channel vanilloid type 2 in red cells of cannabis consumer	29
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy	29
Primary myelofibrosis in a patient with sickle cell disease	29
LLM Abstracts Supplement	28
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?	28
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia	28
Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia—aCML)	28
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	28
Pearson syndrome	28
Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type	27
Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis	27
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia	27
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study	27
Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers	26
Tissue factor activity is increased in neutrophils from JAK2 V617F‐mutated essential thrombocythemia and polycythemia vera patients	26
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort Study	26
Clinical Factors Associated With Catheter‐Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi‐Center Study	26
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy	26
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study	26
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis	26
Superior GVHD‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remissi	26
Ex Vivo IL‐15‐Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Leukemia	26
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation	26
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort	25
Hemolytic anemia and macrothrombocytopenia: A lipid problem?	25
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial	24
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma	24
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants	24
Innovation Alone Is Not Enough: The Urgent Need for Equitable Access in Thalassemia Care	24
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells	23
The Diversity of Spiculated Erythrocytes	23
Elevated MCHC reveals a Southeast Asian Ovalocytosis	23
A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic	22
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B‐Cell Lymp	22
Thirteen‐month‐old girl with hyporegenerative macrocytic anemia due to Brown–Vialetto–Van Laere syndrome 2	22
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management	22
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria	22
TACI variants as underlying condition in autoimmune neutropenia: Description of four cases	22
The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1: A 10‐year retrospective study	22
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma	22
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia	22
Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events	22
Table of Contents	21
2025 update on clinical trials in immune thrombocytopenia	21
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia	21
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	21
Issue Information	21
Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients	21
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia	21
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	21
	21
The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial	21
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing	20
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study	20
Peripheral CD5+ CD10+ B‐cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation	20
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation	20
Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial	20
SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey	20
‘Phenoconversion’ in adult patients with β‐thalassemia	20
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept	20
Unusual complications in the management of chronic lymphocytic leukemia	20
Myopathy related to chronic Graft‐Versus‐Host Disease: From clinic to histological & immunological characterization by imaging mass cytometry	19
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis	19
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial	19
Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia	19
Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis	19
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers	19
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated mult	19

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms	19
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by	19
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma	19
Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma	18
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition	18
Management of post‐autologous transplant relapse in patients with T‐cell lymphomas	18
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invader	18
Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?	18
Correction to “Efficacy and Safety of Early‐Start Deferiprone in Infants and Young Children With Transfusion‐Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Dou	18
Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma	18
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph‐positive leukemias	18
RETRACTION: A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation	18
Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study	18
Table of Contents	18
The pleiotropic effects of α‐thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co‐transport activity, serum erythropoietin, and transfusion burden, do	18
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial	18
Generating Off‐the‐Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells	18
Issue Information	18
Nobel prize in physiology or medicine 2021, receptors for temperature and touch: Implications for hematology	18
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple	17
A 29‐gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival	17
Complement biology for hematologists	17
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies	17
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single‐arm, phase	17
Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features	17
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort	17
Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia	17
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria	17
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management	17
A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa	17
High incidence of malaria in patients with sickle cell disease	17
ALK‐positive histiocytosis of external auditory canal in a 3‐year‐old boy	17
Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease	17
Hyperparathyroidism and the Hematologist	17
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?	17
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or	17
Peripheral blood evidence of iron overload	17
Space anemia unexplained: Red blood cells seem to be space‐proof	17
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?	17
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma	17
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes	17
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	17
	16
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?	16
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	16
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study	16
	16
	16
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA	16
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	16
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study	16
	16
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	16
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan	16
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	16
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia	15
Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7‐targeted Chimeric Antigen R	15
Issue Information	15
Crystal‐storing lymphocytosis	15
TRAF3 alterations are frequent in del‐3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features	15
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms	15
Thalassemia enters a new age … And more lies ahead	15
Increased risk of venous thromboembolism in patients with gastrointestinal disorders	15
Molecular and clinical characterization of transient antithrombin deficiency: A new concept in congenital thrombophilia	15
DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1	15
Rate of major bleeding with ibrutinib versus bendamustine‐rituximab in chronic lymphocytic leukemia: A population‐based cohort study	15
Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis	15
Correction to “Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis”	15
	15
Residual Cerebrovascular Morbidity Despite Treatment in Pediatric Sickle Cell Disease Highlights Opportunities for Earlier, Intensified Monitoring and Treatment	15
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment	15
Changing hemostatic management in post‐partum hemorrhage	15
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort	14
Circulating rhabdoid tumor cells in the peripheral blood of a neonate	14
The prognostic value of blood cellular indices in pulmonary embolism	14
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring	14
Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review	14
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study	14
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy	14
Issue Information	14
Clonal hematopoiesis in unexplained cytopenias	14
It's More Than Complex: Further Insights Into TP53 in MPN	14
Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy	14
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria	14
Poor Engraftment After Posttransplant Cyclophosphamide Graft‐Versus‐Host Disease Prophylaxis in Patients With Myelofibrosis	14
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study	14
Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study	14
Issue Information	14
Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells	14
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	14
Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators	14
Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable	14
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases	14
Fulminant intravascular hemolysis resulting from Clostridium perfringens infection	14
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms	14